Comparison of the efficacy of 3 drugs in prevention of side effects of radioiodine therapy in thyroid cancer patients
Phase 2
Completed
- Conditions
- Thyroid carcinoma.Malignant neoplasm of thyroid gland
- Registration Number
- IRCT2013061713705N1
- Lead Sponsor
- Vice chancellor for research, Shahid Beheshti University Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
1- All the patients affected by differentiated thyroid carcinoma.
2- All the patients for whom total thyroidectomy is done.
Exclusion criteria:
1- Pregnant women
2- Lactating women
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method ausea. Timepoint: Daily for 3 days. Method of measurement: Check list(Mild, Moderate, and severe).;Vomiting. Timepoint: Daily for 3 days. Method of measurement: check list (has, or has not).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antiemetic effects of Patoprazole, Metoclopramide, and Ondansetron in I-131-treated thyroid cancer patients?
How does the efficacy of Patoprazole compare to standard-of-care antiemetics in managing radioiodine-induced gastrointestinal symptoms?
Are there specific biomarkers that predict response to antiemetic drugs in thyroid carcinoma patients undergoing radioiodine therapy?
What are the potential adverse events associated with Metoclopramide and Ondansetron in thyroid cancer patients receiving I-131 treatment?
What combination therapies or alternative drugs are being explored alongside antiemetics for mitigating radioiodine therapy side effects in thyroid malignancies?